Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.ATHA · Entity 1487 | Chief Medical Officer | January 04, 2024 | January 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date January 04, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,482 |
Reported balance
After 2024-01-04 transaction · row 1
1 source rowRow 1 · 2024-01-04 · Grant · Acquired 10,000 · Balance 91,482 F1: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date. F2: On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 10,000 RSUs vested and settled on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date.
F2: On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 10,000 RSUs vested and settled on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2024 Filed Jan 8, 2024 21:45 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001157 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,482 F1 · date: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date. F2 · shares: On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 10,000 RSUs vested and settled on such date. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 23:35 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,882 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-23-034886 · doc4.xml · derivative · entry 3 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,882 shares Expires 2029-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 23:35 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 7,882 | $1.35 | $10,640.70 |
DisclosureSEC source: 0001209191-23-034886 · doc4.xml · nonDerivative · entry 2 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2023 Filed Jun 6, 2023 23:35 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 7,764 | $2.41 | $18,711.24 |
DisclosureSEC source: 0001209191-23-034886 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,600 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 22:53 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001209191-23-004480 · doc4.xml · derivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-01-18 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter. Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 00:10 UTC | LeonaBio, Inc. ATHA · Entity 1487 | PurchaseCommon Stock | 5,000 | $3.29 | $16,442.00 |
DisclosureSEC source: 0001209191-22-057721 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,836 Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 22:06 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,881 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-22-053869 · doc4.xml · derivative · entry 2 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,882 Underlying: Common Stock · 7,881 shares Expires 2029-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 22:06 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 7,881 | $1.35 | $10,639.35 |
DisclosureSEC source: 0001209191-22-053869 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:00 UTC | LeonaBio, Inc. ATHA · Entity 1487 | PurchaseCommon Stock | 10,000 | $2.88 | $28,800.00 |
DisclosureSEC source: 0001209191-22-039937 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,955 Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:54 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039343 · doc4.xml · nonDerivative · entry 2 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,955 F4 · shares: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout") and (3) one third (1/3rd) of the number of shares subject to the RSU award vest six (6) months after the LIFT-AD Readout, in each case subject to continued service with the Issuer through the applicable vesting date. On June 22, 2022, the Issuer completed the public readout of topline results of the ACT-AD Phase 2 clinical trial and 10,000 RSUs vested and settled on such date. Read SEC document |
| May 18, 2022 Filed Jun 24, 2022 23:54 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 1,699 | $7.06 | $11,994.94 |
DisclosureSEC source: 0001209191-22-039343 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,955 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:25 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001209191-22-004120 · doc4.xml · derivative · entry 2 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2032-01-17 F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter. Read SEC document |
| November 18, 2021 Filed Jan 20, 2022 22:25 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 829 | $12.51 | $10,370.79 |
DisclosureSEC source: 0001209191-22-004120 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,256 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021. Read SEC document |
| July 21, 2021 Filed Jul 21, 2021 20:47 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,762 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-21-047601 · doc4.xml · derivative · entry 5 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,763 Underlying: Common Stock · 15,762 shares Expires 2029-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter. Read SEC document |
| July 21, 2021 Filed Jul 21, 2021 20:47 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,610 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-21-047601 · doc4.xml · derivative · entry 4 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,610 shares Expires 2029-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option fully vested on April 1, 2021. Read SEC document |
| July 21, 2021 Filed Jul 21, 2021 20:47 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 15,762 | $1.35 | $21,278.70 |
DisclosureSEC source: 0001209191-21-047601 · doc4.xml · nonDerivative · entry 3 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2021 Filed Jul 21, 2021 20:47 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 12,610 | $1.35 | $17,023.50 |
DisclosureSEC source: 0001209191-21-047601 · doc4.xml · nonDerivative · entry 2 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed Jul 21, 2021 20:47 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 2,055 | $14.45 | $29,694.75 |
DisclosureSEC source: 0001209191-21-047601 · doc4.xml · nonDerivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,055 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of September 17, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began September 17, 2020. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the initial public offering price from the issuer's initial public offering. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 22:39 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-21-012823 · doc4.xml · derivative · entry 1 MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2031-02-17 F1 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.